{"id":"W927234285","doi":"10.1212/wnl.80.7_supplement.s31.004","title":"Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004)","year":2013,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital; University of Toronto; McGill University; University of British Columbia","funders":"","keywords":"Ocrelizumab; Relapsing remitting; Multiple sclerosis; Medicine; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002580608,0.001252278,0.001768186,0.0003249048,0.0004946964,0.0008040269,0.0006091354,0.001558036,0.007955437],"category_scores_gemma":[0.002364389,0.0004984121,0.001613991,0.0002689919,0.0005887414,0.0007352154,0.0003581413,0.003358452,0.001538275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000437644,"about_ca_system_score_gemma":0.0007280087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003994421,"about_ca_topic_score_gemma":0.0008881243,"domain_scores_codex":[0.9992728,0.0003939135,0.00006158641,0.000107839,0.00006532498,0.00009867296],"domain_scores_gemma":[0.9985343,0.0003397191,0.0004220943,0.0001659989,0.0001425416,0.0003953243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9364314,0.01375131,0.003314747,0.0005140678,0.001637771,0.00007934628,0.00007257023,0.0006538457,0.01144746,0.00006254328,0.003136444,0.02889849],"study_design_scores_gemma":[0.8133533,0.164419,0.01578538,0.00005334527,0.001270717,0.0001064462,0.00001918806,0.0002195538,0.002689647,0.0001637084,0.001891084,0.00002858936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847388,0.003088221,0.0005583715,0.0006357893,0.0002449546,0.002799873,0.003972185,0.0001421398,0.003819586],"genre_scores_gemma":[0.9819781,0.001114348,0.00168551,0.0009336279,0.0002948797,0.003422436,0.004848768,0.00006147687,0.005660923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007955437,"threshold_uncertainty_score":0.02661359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03722467554698976,"score_gpt":0.3017990581945809,"score_spread":0.2645743826475911,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}